Catechol estrogens are major estrogen metabolites in mammals and are the most potent naturally occurring inhibitors of catecholamine metabolism. These estrogen compounds have been implicated in carcinogenic activity and the 4/2-hydroxyestradiol concentration has been shown to be elevated in neoplastic human mammary tissue compared to normal human breast tissue. Three human liver UDP-glucuronosyltransferases, UGT2B7, UGTIAI, and UGT1A3, have been shown to catalyze the glucuronidation of catechol estrogens and lead to their enhanced elimination via urine or bile. The present study was designed to study the kinetic interaction of expressed human UGT2B7(Y) or (H), UGTIAI, and UGT1A3 toward 2-and 4-hydroxycatechol estrogens. cDNAs encoding UGT2B7(Y) or (H), UGTIAI, and UGT1A3 were expressed in HK293 cells, and cell homogenates or membrane preparations were used to determine their glucuronidation ability. UGT2B7(Y) reacted with higher efficiency toward 4-hydroxyestrogenic catechols, whereas UGTIAI and UGT1A3 showed higher activities toward 2-hydroxyestrogens. UGT2B7(H) catalyzed estrogen catechol glucuronidation with efficiencies similar to UGT2B70Q. Flunitrazepam (FNZ), a competitive inhibitor of morphine glucuronidation in hepatic microsomes, competitively inhibited catechol estrogen glucuronidation catalyzed by UGT2B7(Y), UGTIAI, and UGT1A3. Buprenorphine, an opioid substrate that reacts at high efficiency with each of these UGTs, was also studied. FNZ competitively inhibited buprenorphine glucuronidation with UGTIAI and UGT2B7 but had no inhibitory activity toward UGT1A3. This suggests that buprenorphine and 2-hydroxycatechol estrogens react with separate active sites of UGT1A3. A catecholamine, norepinephrine, did not inhibit UGT2B7(Y>» UGT1A1-, and UGTlA3-catalyzed glucuronidation of catechol estrogens. These results also suggest that drug-endobiotic interactions are possible in humans and may have implication in carcinogenesis. c 1998 Soday a Toxicology.
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Glucuronidation is an important metabolic process of converting many xenobiotics and endobiotics to more hydrophilic compounds that can be more readily excreted from the body (Dutton, 1980) . These reactions are catalyzed by UDP-glucuronosyltransferases (UGTs) 2 which are located on the luminal side of the endoplasmic reticulum and in the nuclear envelope of cells of the liver and other organs. Currently, over 40 different UGT isoforms of a number of species have been identified through cloning and expression. Based on evolutionary divergence, at least two UGT gene families have been described: UGT1 and UGT2 (Mackenzie et al, 1997) . Members of the UGT I gene complex are encoded by at least 12 first exons (2nd, 11th, and 12th are pseudogenes) and share common second through fifth exons, leading to protein products with a unique N-terminal and common C-terminal domains (Ritter et al, 1992b) . In contrast, gene products of the UGT2 family are transcribed from unique genes (Mackenzie et al, 1990; Haque etal, 1991) .
We have shown that human UGTIAI, often termed "bilirubin" UGT due to its reactivity with this important endobiotic, also catalyzes the glucuronidation of opioid chemicals, such as the agonist/antagonist buprenorphine, with very high efficiency (King et al., 1996) . Also, Coffman et al. (1997) isolated another human UGT, UGT2B7, with a very high catalytic efficiency toward opioid compounds. The deduced amino acid sequence of this protein was identical to the UGT2B7 variant reported by Jin et al. (1993) . It differed slightly from a previously published human liver microsomal UGT termed UGT2B7 by only one amino acid (tyrosine for histidine at position 268) (Ritter et al, 1990) . We have designated the histidine form as UGT2B7(H) and the tyrosine form as UGT2B7(Y) according to accepted official nomenclature (Mackenzie et al, 1997) and each form has been cloned and stably expressed in HK293 cells in our laboratory (Coffman et al, 1997 (Coffman et al, , 1998 . UGT1A3 is the protein product encoded by the splicing of exon lc of the UGT I gene with common exons 2-5, and the expressed protein was shown to react with estrone and 2-hydroxyestrone (Mojarrabi et al., 1996) . However, the reactivity of this protein with other catechol estrogens was not examined.
Catechol estrogens are possibly the most potent naturally occurring inhibitors of catecholamine metabolism because of their structural similarity (Merriam and Lipsett, 1983) . Therefore, high circulating levels of unconjugated catechol estrogens have potential pharmacological and toxicological significance. Indeed, they have been implicated in carcinogenic activity (Liehr and Ricci, 1996) . In transient and stable expression systems, certain members of the UGT1A and 2B families have been shown to catalyze catechol estrogen glucuronidation but kinetic comparisons have not been conducted (Senafi et al., 1994; Mojarrabi et al., 1996; Ebner et al, 1993; Jin et al, 1993) . The purpose of the present study was to characterize the glucuronidation kinetics and efficiency of expressed human UGTs with catechol estrogens. In addition, the interaction of another endogenous catechol, norepinephrine, with the metabolism of catechol estrogens was examined. Finally, flunitrazepam (FNZ), a xenobiotic inhibitor of opioid metabolism (Thomassin and Tephly, 1990) , was examined to determine if it would inhibit catechol estrogen glucuronidation catalyzed by UGT1A1, UGT1A3, and UGT2B7(Y).
MATERIALS AND METHODS

Chemicals. UDP-[U-
u C]GlcUA (311 mCi/mmol) was purchased from ICN Pharmaceuticals (Irvine, CA). Aglycone substrates and flunitrazepam were obtained from Sigma Chemical Co. (St. Louis, MO). The mammalian expression vector pcDNA3 was acquired from Invitrogen (San Diego, CA). Saccharolactone, phosphatidyl choline, UDP-GlcUA, dithiothreitol, and geneticin (G418) were obtained from Sigma. Protein assay reagents were from Bio-Rad (Hercules, CA). All other reagents were of analytical grade.
Expression of human UGT proteins.
The isolation of cDNAs encoding human UGT2B7(Y), UGT1A1, and UGT 1 A3 have been described previously (Coffman et ai, 1997; Mojarrabi et al., 1996; Ritter et al., 1991) . UGT2B7(H) was generated from UGT2B7(Y) using site-directed mutagenesis (QuickChange, Stratagene, La Jolla, CA) as described by Coffman et al. (1998) . HK293 cells were grown in Dulbecco's modified Eagle's medium containing 4.5 mM glucose, 10 mM Hepes, and 10% fetal bovine serum in a humidified incubator, with an atmosphere of 5% CO 2 , at 37°C. HK293 cells were transfected at 10-20% confluency using a calcium phosphate method (Chen et ai, 1988) . Forty-eight hours after transfection, the cells transfected with pcDNA3-UGT2B7(Y), pcDNA3-UGT2B7(H), and pcDNA3-UGTlAl were split and grown in medium containing 700 jig G418/ml to establish stable transfectants, whereas the cells transfected with pCMV5-UGTlA3 were harvested by scraping and frozen at -80°C until used.
Membrane preparations of human UGTs. Membrane preparations were obtained by a modification of the method described previously (Battaglia el ai, 1994) . Freshly harvested HK293 cells stably expressing UGT1A1 or UGT2B7(Y) or (H) were washed three times with phosphate-buffered saline. The cells were then resuspended in 0.25 M sucrose, containing 5 mM Hepes (pH 7.4). A homogenate was obtained by the disruption of the cells using a tissue tearer (Bio Spec, Racine, WI) for 10 s. The cell homogenates were then sonicated three times with 10-s bursts using a Sonifier cell disruptor (Ultrasonics, Plainview, NY). The cells were homogenized by hand with a PotterElvehjem homogenizer, 10 strokes, followed by centrifugation at 9000g for 20 min. The supematants were then centrifuged at 100,000g for 60 min. The resulting pellets were overlaid with 0.25 M sucrose, containing 5 mM Hepes (pH 7.4) and stored at -80°C until used. Note. Data shown are either the mean values from two experiments using the same membrane preparation or the mean ± SD of determinations from at least three transfections. The UDP-GlcUA concentration was 2.0 mM, and the substrate concentration was 0.1 mM.
Glucuronidation assays. Membrane preparations from HK293 cells stably expressing UGT1A1 or UGT2B7(Y) or (H) were suspended in 10 mM Trisbuffered saline (pH 7.4) containing 0.5 mM dithiothreitol. HK293 cells expressing UGT 1 A3 were subjected to three rounds of freeze-thawing prior to homogenization. Glucuronidation activity toward catechol estrogens was assayed using a modification of the extraction method described by Matern et al. (1994) . Briefly, all assay mixtures (100 /il total volume) contained 50 mM Tris-HCl, 10 mM MgCI 2 , 100 /xg phosphatidylcholine/ml, 8.5 mM saccharolactone, 2 mM UDP-GlcUA, and varying concentrations of catechol estrogens. All the enzyme assays were carried out at pH 7.4 with 0.1 mg of protein at 37°C for 1 h. Membranes from nontransfected HK293 cells and pcDNA3-and pCMV5-transfected HK293 cells showed no glucuronidation activity toward the catechol estrogens tested in this study.
The apparent K m values for the aglycones were determined at the optimal pH, protein concentration, and reaction times yielding linear product formation. The apparent K m for catechol estrogens was determined by varying the concentration of aglycones from approximately -to 10 times the estimated K m using 2 mM UDP-GlcUA. The glucuronide extraction method of Matern et al. (1994) was used for catechol estrogens and opioid glucuronidation was determined using the method described by Puig and Tephly (1986) . Kinetic parameters were calculated using the Enzyme Kinetics program (Trinity Software, Plymouth, NH). Inhibition studies were conducted in the presence and absence of flunitrazepam in ambient light. FNZ was dissolved in DMSO, and DMSO alone served as a vehicle control. The inhibition constant (K t ) was derived by the Dixon method and the inhibition was determined to be competitive in each case.
RESULTS
Glucuronidation of catechol estrogens by expressed UGT1A1, UGT1A3, and UGT2B7(Y).
Membrane preparations or cell homogenates derived from HK293 cells expressing human UGTIA1, UGT1A3, and UGT2B7(Y) catalyzed the glucuronidation of a number of catechol estrogens (Table 1) . Data obtained with UGT2B7(H) were similar to those obtained with UGT2B7(Y). Therefore, only activities from UGT2B7(Y) will be shown. Of the catechol estrogens tested, 4-hydroxyestrogenic catechols showed higher glucuronidation rates with UGT2B7(Y), while 2-hydroxyestrogens such as 2-hydroxyestrone and 2-hydroxyestradiol displayed much lower rates. In contrast to results obtained with expressed UGT2B7(Y), expressed UGT1A1 catalyzed the glucuronidation of 2-hydroxyestrogens at higher rates. 4-Hydroxyestrone and 4-hydroxyestradiol also reacted with expressed UGT1A1, but their glucuronidation rates were considerably lower compared to those values for catechol estrogens were determined using 2.0 mM UDP-GlcUA and the results of two different determinations of 2-hydroxyestrogenic catechols. Transiently expressed human UGT1A3 also catalyzes the glucuronidation of catechol estrogens and 2-hydroxycatechol estrogens are glucuronidated at 10-fold higher rates compared to 4-hydroxycatechol estrogens (Table 1 ). These data show that 4-hydroxyestrogens display higher rates for UGT2B7(Y) and 2-hydroxyestrogens show higher rates for UGT1A1 and UGT1A3. In contrast, UGT1A4, which is 90% homologous to UGT1A3, does not glucuronidate either 2-or 4-hydroxyestrone and reacts with 2-and 4-hydroxyestradiol with very low activities .
Kinetic analysis of glucuronidation catalyzed by expressed human UGT1A1, UGT1A3, and UGT2B7(Y).
Kinetic analysis was carried out for 2-and 4-hydroxyestrogenic substrates using membrane preparations or cell homogenates from HK293 cells expressing UGT1A1, UGT1A3, and UGT2B7(Y). All of the 4-hydroxyestrogens studied displayed very high efficiency values (V^JKm) with UGT2B7(Y). The glucuronidation efficiency obtained with UGT2B7(Y) for 4-hydroxyestrone was approximately 8 fold higher than that observed for 4-hydroxyestradiol (Table 2) . Membrane preparations derived from HK293 cells which stably expressed UGT1A1 yielded high catalytic efficiency toward 2-hydroxyestrogenic catechols, and the glucuronidation efficiencies of 2-hydroxyestrone and 2-hydroxyestradiol were very similar. Cell homogenates were used to study UGT1A3 glucuronidation ability of catechol estrogens. UGT1A3 reacts with 2-hydroxycatechol estrogens with 10-fold higher efficiencies compared to those found for 4-hydroxycatechol estrogens. Based on the data presented in Tables  1 and 2 UGT2B7 (Y) appears to be a major enzyme involved in the 4-hydroxycatechol estrogen glucuronidation in humans, whereas UGT1A1 and UGT1A3 appear to be the major UGTs in the glucuronidation of 2-hydroxyestrogenic catechols.
Inhibition of catechol estrogen glucuronidation. Although 2-hydroxyestradiol serves as a poor substrate for UGT2B7(Y) (Tables 1 and 2) , it is an inhibitor of 4-hydroxyestradiol glucuronidation catalyzed by UGT2B7(Y) ( Table 3) . A 30% inhibition was seen at 0.05 mM and about a 50% inhibition was observed at 0.1 mM. Also, 4-hydroxyestradiol is an efficient inhibitor of 2-hydroxyestradiol glucuronidation catalyzed by UGT1A1 (Table 3) ; 75 and 83% inhibition was observed at 0.05 and 0.1 mM concentrations of inhibitor, respectively. Interestingly, 4-hydroxyestradiol does not inhibit 2-hydroxyestradiol glucuronidation catalyzed by UGT1A3 (Table 3) . This is not due to the use of cell homogenates instead of membrane preparations since when cell homogenates were used for UGT1A1, identical inhibition results were obtained compared to results using membrane preparations (data not shown). A catecholamine, norepinephrine, did not inhibit UGT2B7(Y>, UGT1A1-, or UGTlA3-catalyzed glucuronidation of catechol estrogens. We have also found that norepinephrine was not glucuronidated by any of these three UGT isoforms (data not shown). Thomassin and Tephly (1990) showed that FNZ competitively inhibited morphine glucuronidation in rat liver microsomes and that this benzodiazepine could serve as a photoaffinity ligand. Since our laboratory has also shown that the major catalysts of opioid glucuronidation in human liver are UGT2B7, UGT1A1, and UGT1A3 (King et aL, 1996; Coffman et aL, 1997; Green et al., 1998) , and since these proteins also catalyze catechol estrogen glucuronidation, studies on the Note. Data represent mean values from at least two experiments of the same membrane preparation or cell homogenate. UDP-GlcUA concentration was 2.0 mM, and substrate concentration was 0.03 mM. The inhibitors' concentration is indicated in the table. -, the experiment was not carried out.
Inhibition of human UGTs by FNZ
" pmol/min/mg protein. inhibition of catechol estrogen and opioid glucuronidation catalyzed by these isoforms were carried ouL FNZ competitively inhibited catechol estrogen and buprenorphine glucuronidation catalyzed by UGT1A1 and UGT2B7(Y) (Figs. 1A and IB) . The apparent inhibition constant (AT;) of FNZ with UGT2B7(Y) was about the same when used as an inhibitor of catechol estrogen or opioid glucuronidation (Table 4 ), suggesting that FNZ inhibits the binding of catechol estrogens and opioids to UGT2B7(Y) at the same site. In contrast, the K { of FNZ with UGT1 Al and catechol estrogens was approximately 10-to 20-fold higher than that observed with UGT2B7(Y) (Table 4) . Thus, FNZ is a much less efficient inhibitor for the glucuronidation of catechol estrogens as catalyzed by UGT1A1. Surprisingly, FNZ does not inhibit buprenorphine glucuronidation catalyzed by UGT1A3, though it inhibits UGTlA3-catalyzed catechol estrogen glucuronidation very effectively (Table 4) .
DISCUSSION
The current study shows the glucuronidation efficiencies of UGT1A1, UGT1A3, and UGT2B7 isoforms in their reactions with 2-and 4-hydroxycatechol estrogens. UGT2B7 preferen- tially catalyzes the glucuronidation of 4-hydroxycatechol estrogens whereas UGT1A1 and UGT1A3 efficiently catalyze the glucuronidation of 2-hydroxyestrogenic catechols. Previous studies have shown high glucuronidation activities for expressed human UGT1A1 (Senafi et al., 1994) , UGT1A3 (Mojarrabi et al, 1996) , UGT1A9 (Ebner et al., 1993) , and UGT2B7 (Jin et al., 1993) toward catechol estrogens and very low catechol estrogen glucuronidation activities have been found for expressed UGTIA4 , 2B4 (Ritter et al., 1992a,b) , and 2B15 (Green et al., 1994) . However, these studies did not address the efficiency or affinity of 2-and 4-hydroxycatechol estrogen substrates with UGTs. The differences observed Ln the efficiency of glucuronidation of the 2-or 4-hydroxycatechol estrogens are probably not due to differences in their binding affinity to the UGTs, since 2-and 4-hydroxycatechol estrogens display similar apparent K m values with each of the UGT isoforms studied. Therefore, the differences in efficiency of turnover for glucuronidation of catechol estrogens observed may be due to differences in energetics of the reactions. Another possible explanation for differential catechol estrogen activity relates to the site of glucuronidation. Expressed UGT2B7 does not glucuronidate estrone (Ritter et al., 1990) , has low glucuronidation efficiency with 2-hydroxyestrone, and has high glucuronidation efficiency with 4-hydroxyestrone. This suggests that the glucuronic acid may be preferentially conjugated to the 4-hydroxyl position of the A ring. On the other hand, UGT1A1 does not catalyze glucuronidation of estrone (King et al., 1996) has low glucuronidation activity toward 4-hydroxyestrone and high activity with 2-hydroxyestrone. This suggests that UGT1A1-catalyzed 2-hydroxyestrone glucuronidation preferentially occurs at the 2-hydroxyl position of the catechol ring. 4-Hydroxycatechol estrogens are recognized as potent carcinogenic agents in vivo (Liehr, 1998) . This toxicologic property of 4-hydroxycatechol estrogens may be due to their high affinity for estrogen receptors and/or their potential for causing oxygen radical formation by redox cycling (Liehr, 1998) . It has been suggested that elevated tissue concentrations of 4-hydroxycatechol estrogens may be due, in part, to the preferential inhibition of their conversion to phase II metabolites compared to 2-hydroxycatechol estrogens (Liehr, 1998) . The inhibition of phase PI metabolism has been suggested by Liehr (1998) to be mediated by 2-hydroxycatechol estrogens or by catecholamines. In our study, we show that 4-hydroxyestradiol is a potent inhibitor of 2-hydroxyestradiol glucuronidation catalyzed by UGT1 Al, whereas 2-hydroxyestradiol is a less potent inhibitor of 4-hydroxyestradiol glucuronidation catalyzed by UGT2B7. These results contrast with those observed for catechol-O-methyltransferase, where 2-hydroxycatechol estrogens are potent inhibitors of 4-hydroxycatechol estrogen methylation (Liehr, 1998) . In the present study, we also show that 50 yM norepinephrine did not inhibit glucuronidation of either 2-or 4-hydroxycatechol estrogens catalyzed by expressed UGT1A1 and UGT2B7, respectively. Therefore, it is unlikely that catecholamines significantly inhibit glucuronidation of catechol estrogens in vivo. Because catechol estrogens are too short lived to be circulating hormones (Merriam and Lipsett, 1983) , their postulated role as local mediators of estrogen action implies a need for inactivating enzymes close to sites of formation of catechol estrogens. Thus, further studies are needed to explore the expression of UGT1A1, UGT1 A3, and UGT2B7 in tissues where catechol estrogens might exert their toxic effects. Ciotti and Owens (1996) suggest that human UGT1A1 has overlaping aglycone binding sites for steroids and bilirubin. We examined the effects of FNZ, a xenobiotic inhibitor of opioid glucuronidation, to determine if it would inhibit catechol estrogen glucuronidation catalyzed by UGT1A1, UGT1A3, and UGT2B7. FNZ had been shown previously to competitively inhibit morphine glucuronidation in rat hepatic microsomes (Thomassin and Tephly, 1990 ) and we have shown that UGT2B7 (Coffman et al., 1997 ) is a major human liver enzyme for morphine glucuronidation. FNZ competitively inhibits opioid and 4-hydroxycatechol estrogen glucuronidation catalyzed by expressed human UGT2B7. In addition, FNZ is a competitive inhibitor of buprenorphine and 2-hydroxycatechol estrogen glucuronidation catalyzed by UGT1A1. The similarity of the K { values for FNZ toward opioid and estrogen catechol glucuronidation suggests that opioid and catechol estrogen interact with UGT2B7 and UGT1A1 at or about the same catalytic site. FNZ is also a potent inhibitor of 2-hydroxycatechol estrogen glucuronidation as catalyzed by UGT1A3 but, surprisingly, does not inhibit buprenorphine glucuronidation. Thus, this argues for different active sites for catechol estrogens and buprenorphine with UGTl A3. The ability of FNZ to interact with binding sites of catechol estrogen and opioid with UGTl A3 may prove to be of value in photolabling studies since FNZ has been a useful photoaffinity labeling agent Because benzodiazepines, like FNZ, are potent competitive inhibitors of catechol estrogen glucuronidation with human UGT1A1, UGT1A3, and UGT2B7, drug-endobiotic interactions should also be considered when benzodiazepines are employed for therapeutic purposes.
